Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 16/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836751 | 0.92 | CYP11B2 (0.67) | CYP11B1CYP11B2NR3C1PGR | |
| SCHEMBL6182232 | 0.87 | NR3C1 (0.70) | CYP11B1CYP11B2NR3C1NPBWR1PGR | |
| SCHEMBL27787547 | 0.85 | NR3C1 (0.55) | CYP11B1CYP11B2NR3C1PGR | |
| SCHEMBL4784971 | 0.85 | NR3C1 (0.63) | CYP11B1CYP11B2NR3C1PGR | |
| SCHEMBL27765743 | 0.84 | NR3C1 (0.58) | CYP11B1CYP11B2NR3C1PGR | |
| SCHEMBL6183317 | 0.84 | PGR (0.55) | CYP11B1CYP11B2NR3C1ALDH1A1NPBWR1 | |
| SCHEMBL27787555 | 0.82 | NR3C1 (0.55) | CYP11B1CYP11B2NR3C1PGR | |
| SCHEMBL27787554 | 0.81 | NR3C1 (0.54) | CYP11B1CYP11B2NR3C1NPBWR1PGR | |
| SCHEMBL30947618 | 0.81 | CYP11B1 (0.56) | CYP11B1CYP11B2NR3C1ALDH1A1NPBWR1 | |
| SCHEMBL13486135 | 0.80 | NR3C1 (0.50) | CYP11B1CYP11B2NR3C1NPBWR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919332-B2 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030232849-A1 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232849-A1 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP8, MMP9, MMP1 | CYP11B1 585/4885CYP11B2 702/4885NR3C1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.